The NeurologyLive® movement disorders clinical focus page is a source for all the latest news regarding the clinical care of patients with Parkinson disease, essential tremor, Huntington disease, dystonia, ataxia, and more. This page features podcasts, videos, and news about FDA actions, study and clinical trial findings, clinical guideline updates, and interviews with experts in the clinical care of movement disorders.
August 25th 2025
Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 4th Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress.
Side Effects of Apomorphine Usage in Parkinson’s Disease
A panel of experts debate the disadvantages and side effects of apomorphine therapies for Parkinson’s disease.
Subcutaneous ABBV-951 Infusion Superior in Parkinson Disease to Oral Formulation
November 11th 2021Those who received an infusion of ABBV-951, consisting of foslevodopa/foscarbidopa, showed statistically significant increases in hours of ON time without troublesome dyskinesia compared with oral levodopa/carbidopa.
Preoperative RBD Not Linked to Altered Outcomes in Post DBS Parkinson Disease
November 11th 2021Twelve months after subthalamic deep brain stimulation, patients with and without RBD had MDS-UPDRS IV score decrease, MDS-UPDRS III MedOff decrease, and total LEDD decrease, with no between group difference.
Dose-Dependent Association Identified Between Parkinson Disease and Physical Activity
November 4th 2021Performing physical activity after receiving a diagnosis of Parkinson disease was associated with a decreased mortality rate, even in individuals with PD who were physically inactive before diagnosis.
Important Attributes of On-Demand Therapies for Parkinson’s Disease
Key opinion leaders explain the important attributes to consider when choosing an on-demand therapy.
A New Approach to Protein Misfolding in Parkinson Disease
October 30th 2021Previously, many promising treatments for PD have ultimately resulted in untenable adverse effects or in failure, but the evolving area of protein folding offers an opportunity to slow or reverse the neurodegenerative process.